Ten Researchers Honored With Conquer Cancer Merit Awards

Merit Award Emblem

The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) is pleased to announce the recipients of the Clinical Immuno-Oncology Symposium Merit Awards. Conquer Cancer Merit Awards recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to an ASCO-sponsored or cosponsored meeting, and the selected early-career researchers of the Clinical Immuno-Oncology Symposium Merit Awards will present their findings at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, Calif.

The following individuals are 2019 Clinical Immuno-Oncology Symposium Merit Award recipients:

  • Filiz Oezkan, MD, The Ohio State University

Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial. (Abstract 99)

  • David James Pinato, MD, PhD, MRCP, Imperial College London

Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice. (Abstract 147)

  • Arnav Mehta, MD, PhD, Massachusetts General Hospital

Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response. (Abstract 130)

  • Abdul Rafeh Naqash, MBBS, East Carolina University

Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration. (Abstract 118)

  • Ziad Bakouny, MD, MSc, Dana-Farber Cancer Institute

Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). (Abstract 66)

  • Yuanquan Yang, MD, PhD, Roswell Park Comprehensive Cancer Center

Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer. (Abstract 58)

  • Sanjay Chandrasekaran, MD, University of Washington

PTEN/PI3K signaling in cancer and the response to cytokines: From growth factors to immune actors. (Abstract 35)

  • Sophie Feng, MBBS, Princess Margaret Cancer Centre

Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks. (Abstract 17)

  • Sunyoung S. Lee, MD, PhD, Roswell Park Comprehensive Cancer Center

Modeling of prognostication based on genomic expression in the tumor microenvironment of muscle invasive urothelial carcinoma via machine learning. (Abstract 64)

  • Kartik Anand, MBBS, Houston Methodist Cancer Center

T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies. (Abstract 88)

The 2019 Conquer Cancer Foundation of ASCO Merit Awards in clinical immuno-oncology are supported by Anonymous; Agios Pharmaceuticals, Inc.; ASCO Employees; AstraZeneca; Friends and Family of Dr. and Mrs. Ronald Beller; Dr. and Mrs. Douglas W. Blayney; Breast Cancer Research Foundation®; Bristol-Myers Squibb; Jonathan K. and Cora Y. Cho Charitable Fund; Eisai Inc.; Estate of Darla C. Ellis; G1 Therapeutics; GlaxoSmithKline Oncology; Dr. Arti Hurria and Dr. Hyman B. Muss; Ipsen Biopharmaceuticals Inc.; Dr. Michael Kelley and Dr. Elise Hoffman; Kidney Cancer Association; Lilly; Loxo Oncology; Friends and Family of Dr. James B. Nachman; Northern New England Clinical Oncology Society; Dr. Kathleen Pritchard Medicine Professional Corporation; Sarah Cannon Research Institute; Dr. Frances A. Shepherd; Dr. Stephen A. Sherwin; Drs. Rachna and Puneet Shroff; Dr. Nizar M. Tannir; TESARO; and Dr. Michael and Mrs. Deborah Troner.
For more information on the Merit Awards program or instructions on how to apply, visit The 2019 Conquer Cancer Foundation of ASCO Merit Awards in clinical immuno-oncology are supported by Anonymous; Agios Pharmaceuticals, Inc.; ASCO Employees; AstraZeneca; Friends and Family of Dr. and Mrs. Ronald Beller; Dr. and Mrs. Douglas W. Blayney; Breast Cancer Research Foundation®; Bristol-Myers Squibb; Jonathan K. and Cora Y. Cho Charitable Fund; Eisai Inc.; Estate of Darla C. Ellis; G1 Therapeutics; GlaxoSmithKline Oncology; Dr. Arti Hurria and Dr. Hyman B. Muss; Ipsen Biopharmaceuticals Inc.; Dr. Michael Kelley and Dr. Elise Hoffman; Kidney Cancer Association; Lilly; Loxo Oncology; Friends and Family of Dr. James B. Nachman; Northern New England Clinical Oncology Society; Dr. Kathleen Pritchard Medicine Professional Corporation; Sarah Cannon Research Institute; Dr. Frances A. Shepherd; Dr. Stephen A. Sherwin; Drs. Rachna and Puneet Shroff; Dr. Nizar M. Tannir; TESARO; and Dr. Michael and Mrs. Deborah Troner.
For more information on the Merit Awards program or instructions on how to apply, visit CONQUER.ORG/Merit-award